Investor Presentaiton
•
•
Daprodustat: an innovative, convenient oral treatment
for patients with anaemia due to CKD
Strong clinical data supports
competitive commercial profile
Convenient oral option for non-dialysis
and dialysis patients
Flexible dosing: QD1 or TIW² with
iron and phosphate binders
Predictable Hb increase and
maintenance within target level
Improvements in QOL³ including
fatigue (SF-36 vitality score)
Significant market opportunity
>₤2 billion
>£2
US ESA CKD market
>₤1 billion
Europe ESA CKD market
gsk
Leveraging experience to deliver
commercial success
•
Investing behind internal capabilities
• >900 specialty experts hired since
2017
Established leadership position with
nephrologists from Benlysta LN
launch
H1 2022: regulatory submissions
(US, EU)
1. Once daily 2. Three times weekly 3. Quality of life.
24View entire presentation